Compare Charles Schwab Corporation Common Stock (SCHW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Charles Schwab Corporation Common Stock trades at $96.98 (market cap $165.91B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 22.1× Spyre Therapeutics Inc. Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.33% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 86 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SCHW | SYRE | |
|---|---|---|
Market Cap | $165.91B | $7.52B |
Volume | 6,860,399 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $113.65 | $108.92 |
52-Week Low | $85.35 | $22.18 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $152.35B | $6.52B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.80, down 0.27% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported record quarterly revenue of $7.08 billion in Q3 2026 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.69 price target, representing 25% upside potential from current levels.
SCHW demonstrates robust financial health with 38.79% net margins and 22.45% ROE, though technical weakness and competitive pressures in brokerage services present near-term challenges. The stock offers attractive valuation at 17.48x P/E with strong earnings momentum, but investors should monitor interest rate sensitivity and market volatility impacts on trading volumes.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
